Acemoglu, D. and U. Akcigit (2012). Intellectual property rights policy, competition and innovation. Journal of the European Economic Association 10(1), 1–42.
Adams, S. (2008). Globalization and income inequality: Implications for intellectual property rights. Journal of Policy Modeling 30(5), 725–735.
Aghion, P., P. Howitt, and S. Prantl (2015). Patent rights, product market reforms, and innovation. Journal of Economic Growth 20(3), 223–262.
Aghion, P., U. Akcigit, A. Bergeaud, R. Blundell, and D. Hémous (2019). Innovation and top income inequality. The Review of Economic Studies 86(1), 1–45.
- Angell, M. (2005). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House Incorporated.
Paper not yet in RePEc: Add citation now
Arora, A., A. Gambardella, L. Magazzini, and F. Pammolli (2009). A breath of fresh air? Firm type, scale, scope, and selection effects in drug development. Management Science 55(10), 1638–1653.
Arora, A., M. Ceccagnoli, and W. M. Cohen (2008). R&D and the patent premium. International Journal of Industrial Organization 26(5), 1153–1179.
Arora, A., S. Belenzon, and A. Patacconi (2018). The decline of science in corporate R&D. Strategic Management Journal 39(1), 3–32.
- Baker, D., A. Jayadev, and J. E. Stiglitz (2017). Innovation, intellectual property, and development: A better set of approaches for the 21st century. Technical report, Online manuscript retrievable at: https://academiccommons.columbia.edu/doi/10.7916/d8-xg80-ct59.
Paper not yet in RePEc: Add citation now
Baruffaldi, S. H. and M. Simeth (2020). Patents and knowledge diffusion: The effect of early disclosure. Research Policy 49(4), 103927.
Bessen, J. E., J. Bessen, and M. J. Meurer (2008). Patent failure: How judges, bureaucrats, and lawyers put innovators at risk. Princeton: Princeton University Press.
- Best, M. and J. Bradley (2020). World War II to Covid-19: Been here before and done better. Discussion paper, Institute for New Economic Thinking.
Paper not yet in RePEc: Add citation now
Boldrin, M. and D. K. Levine (2013). The case against patents. Journal of Economic Perspectives 27(1), 3–22.
Boldrin, M., D. K. Levine, et al. (2008). Against intellectual monopoly. Cambridge: Cambridge University Press.
Bottazzi, G. and A. Secchi (2005). Growth and diversification patterns of the worldwide pharmaceutical industry. Review of Industrial Organization 26(2), 195–216.
Bottazzi, G., G. Dosi, M. Lippi, F. Pammolli, and M. Riccaboni (2001). Innovation and corporate growth in the evolution of the drug industry. International Journal of Industrial Organization 19(7), 1161–1187.
Budish, E., B. N. Roin, and H. Williams (2015). Do firms underinvest in long-term research? Evidence from cancer clinical trials. American Economic Review 105(7), 2044–85.
Budish, E., B. N. Roin, and H. Williams (2016). Patents and research investments: Assessing the empirical evidence. American Economic Review 106(5), 183–87.
Chiaromonte, F. and G. Dosi (1993). Heterogeneity, competition, and macroeconomic dynamics. Structural Change and Economic Dynamics 4(1), 39–63.
Cimoli, M., G. Dosi, K. E. Maskus, R. L. Okediji, J. H. Reichman, and J. E. Stiglitz (2014). Intellectual property rights: legal and economic challenges for development. Oxford: Oxford University Press.
- Cleary, E. G., J. M. Beierlein, N. S. Khanuja, L. M. McNamee, and F. D. Ledley (2018). Contribution of NIH funding to new drug approvals 2010–2016. Proceedings of the National Academy of Sciences 115(10), 2329–2334.
Paper not yet in RePEc: Add citation now
Coad, A. (2019). Persistent heterogeneity of R&D intensities within sectors: Evidence and policy implications. Research Policy 48(1), 37–50.
Cohen, W. M., R. Nelson, and J. P. Walsh (2000). Protecting their intellectual assets: Appropriability conditions and why US manufacturing firms patent (or not). Working Paper 7552, National Bureau of Economic Research.
Cohen, W. M., R. R. Nelson, and J. P. Walsh (2002). Links and impacts: the influence of public research on industrial R&D. Management Science 48(1), 1–23.
- Coriat, B. and L. Orsenigo (2014). IPRs, public health and the pharmaceutical industry: Issues in the post-2005 TRIPS agenda. In M. Cimoli, G. Dosi, K. E. Maskus, R. L. Okediji, J. H. Reichman, and J. E. Stiglitz (Eds.), Intellectual Property Rights: Legal and Economic Challenges for Development, pp. 219–241. Oxford: Oxford University Press.
Paper not yet in RePEc: Add citation now
de Rassenfosse, G. and K. Higham (2021). Decentralising the patent system. Government Information Quarterly 38(2), 101559.
de Rassenfosse, G., G. Pellegrino, E. Raiteri, et al. (2020). Do patents enable disclosure? Evidence from the Invention Secrecy Act. Working Paper 9, EFPL.
- DiMasi, J. A. and L. B. Faden (2011). Competitiveness in follow-on drug R&D: a race or imitation? Nature Reviews Drug Discovery 10(1), 23–27.
Paper not yet in RePEc: Add citation now
DiMasi, J. A., R. W. Hansen, and H. G. Grabowski (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics 22(2), 151–185.
- Dosi, G. (2007). Statistical regularities in the evolution of industries: A guide through some evidence and challenges for the theory. In Perspectives on innovation, pp. 1110–1121. Cambridge: Cambridge University Press.
Paper not yet in RePEc: Add citation now
Dosi, G. (2021). Some policy lessons from medical/therapeutic responses to the COVID-19 Crisis: A rich research system for knowledge generation and dysfunctional institutions for its exploitation. Intereconomics, forthcoming.
- Dosi, G. and J. E. Stiglitz (2014). The role of intellectual property rights in the development process, with some lessons from developed countries: An introduction. Intellectual property rights: Legal and economic challenges for development 1, 1–55.
Paper not yet in RePEc: Add citation now
Dosi, G., G. Fagiolo, and A. Roventini (2010). Schumpeter meeting Keynes: A policy-friendly model of endogenous growth and business cycles. Journal of Economic Dynamics and Control 34(9), 1748–1767.
Dosi, G., L. Marengo, and C. Pasquali (2006). How much should society fuel the greed of innovators ?: On the relations between appropriability, opportunities and rates of innovation. Research Policy 35(8), 1110–1121.
Dosi, G., L. Marengo, J. Staccioli, and M. E. Virgillito (2021). Big pharma and monopoly capitalism: A long-term view. Working paper series 2021/26, Laboratory of Economics and Management (LEM), Scuola Superiore Sant’Anna, Pisa, Italy.
Dosi, G., M. C. Pereira, and M. E. Virgillito (2016). The footprint of evolutionary processes of learning and selection upon the statistical properties of industrial dynamics. Industrial and Corporate Change 26(2), 187–210.
- Dosi, G., O. Marsili, L. Orsenigo, and R. Salvatore (1995). Learning, market selection and the evolution of industrial structures. Small Business Economics 7(6), 411–436.
Paper not yet in RePEc: Add citation now
Dubois, P., O. De Mouzon, F. Scott-Morton, and P. Seabright (2015). Market size and pharmaceutical innovation. The RAND Journal of Economics 46(4), 844–871.
Fagiolo, G. and G. Dosi (2003). Exploitation, exploration and innovation in a model of endogenous growth with locally interacting agents. Structural Change and Economic Dynamics 14(3), 237–273.
- Fagiolo, G., M. Guerini, F. Lamperti, A. Moneta, and A. Roventini (2019). Validation of agentbased models in economics and finance. In Computer Simulation Validation: Fundamental Concepts, Methodological Frameworks, and Philosophical Perspectives. Springer.
Paper not yet in RePEc: Add citation now
- Freeman, C. (1982). Economics of industrial innovation. London: Frances Pinter.
Paper not yet in RePEc: Add citation now
Fudenberg, D., R. Gilbert, J. Stiglitz, and J. Tirole (1983). Preemption, leapfrogging and competition in patent races. European Economic Review 22(1), 3–31.
Furman, J. L., M. Nagler, and M. Watzinger (2018). Disclosure and subsequent innovation: Evidence from the patent depository library program. Working Paper 24660, National Bureau of Economic Research.
Garavaglia, C., F. Malerba, L. Orsenigo, and M. Pezzoni (2013). A simulation model of the evolution of the pharmaceutical industry: A history-friendly model. Journal of Artificial Societies and Social Simulation 16(4), 5.
Grabowski, H. and J. Vernon (2000). The determinants of pharmaceutical research and development expenditures. Journal of Evolutionary Economics 10(1), 201–215.
Gross, D. P. (2019). The consequences of invention secrecy: Evidence from the USPTO Patent Secrecy Program in World War II. Working Paper 25545, National Bureau of Economic Research.
Gross, D. P. and B. N. Sampat (2021). The economics of crisis innovation policy: A historical perspective. In AEA Papers and Proceedings, Volume 111, pp. 346–50.
Guerini, M. and A. Moneta (2017). A method for agent-based models validation. Journal of Economic Dynamics and Control 82, 125–141.
Hall, B., C. Helmers, M. Rogers, and V. Sena (2014). The choice between formal and informal intellectual property: a review. Journal of Economic Literature 52(2), 375–423.
- Heller, M. A. and R. S. Eisenberg (1998). Can patents deter innovation? The anticommons in biomedical research. Science 280(5364), 698–701.
Paper not yet in RePEc: Add citation now
- Jaffe, A. B. and J. Lerner (2004). Innovation and its discontents: How our broken patent system is endangering innovation and progress, and what to do about it. Princeton: Princeton University Press.
Paper not yet in RePEc: Add citation now
Jaffe, A. B., M. Trajtenberg, and M. S. Fogarty (2000). Knowledge spillovers and patent citations: Evidence from a survey of inventors. American Economic Review 90(2), 215–218.
Kay, N. M. (1979). Innovating Firm: A Behavioural Theory of Corporate R&D. London: Macmillan.
Kong, N., U. Dulleck, A. B. Jaffe, and S. Vajjala (2020). Linguistic metrics for patent disclosure: Evidence from university versus corporate patents. Working Paper 27803, National Bureau of Economic Research.
Kremer, M. (2002). Pharmaceuticals and the developing world. Journal of Economic Perspectives 16(4), 67–90.
Lamperti, F. (2018). An information theoretic criterion for empirical validation of simulation models. Econometrics and Statistics 5, 83–106.
Landini, F. and F. Malerba (2017). Public policy and catching up by developing countries in global industries: a simulation model. Cambridge Journal of Economics 41(3), 927–960.
Landini, F., K. Lee, and F. Malerba (2017). A history-friendly model of the successive changes in industrial leadership and the catch-up by latecomers. Research Policy 46(2), 431–446.
Lanjouw, J. O. and I. M. Cockburn (2001). New pills for poor people? Empirical evidence after GATT. World Development 29(2), 265–289.
Lazonick, W. and M. Mazzucato (2013). The risk-reward nexus in the innovation-inequality relationship: who takes the risks? Who gets the rewards? Industrial and Corporate Change 22(4), 1093–1128.
Levin, R. C., A. K. Klevorick, R. R. Nelson, S. G. Winter, R. Gilbert, and Z. Griliches (1987). Appropriating the returns from industrial research and development. Brookings Papers on Economic Activity 1987(3), 783–831.
- Light, D. W. and J. Lexchin (2005). Foreign free riders and the high price of US medicines. British Medical Journal 331(7522), 958–960.
Paper not yet in RePEc: Add citation now
Malerba, F. and L. Orsenigo (2002). Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a history-friendly model. Industrial and Corporate Change 11(4), 667–703.
Malerba, F. and L. Orsenigo (2015). The evolution of the pharmaceutical industry. Business History 57(5), 664–687.
Malerba, F., R. Nelson, L. Orsenigo, and S. Winter (1999). ’History-friendly’ models of industry evolution: the computer industry. Industrial and Corporate Change 8(1), 3–40.
Malerba, F., R. Nelson, L. Orsenigo, and S. Winter (2001). Competition and industrial policies in a ‘history friendly’ model of the evolution of the computer industry. International Journal of Industrial Organization 19(5), 635–664.
- Mansfield, E. (1968). The economics of technological change. London: Norton.
Paper not yet in RePEc: Add citation now
Mansfield, E. (1986). Patents and innovation: an empirical study. Management Science 32(2), 173–181.
Mansfield, E., M. Schwartz, and S. Wagner (1981). Imitation costs and patents: an empirical study. The Economic Journal 91(364), 907–918.
Marengo, L., C. Pasquali, M. Valente, and G. Dosi (2012). Appropriability, patents, and rates of innovation in complex products industries. Economics of Innovation and New Technology 21(8), 753–773.
- Mazzucato, M., H. L. Li, and A. Darzi (2020). Is it time to nationalise the pharmaceutical industry? BMJ: British Medical Journal 368, m769.
Paper not yet in RePEc: Add citation now
- Nordhaus, W. D. (1969). Invention, growth and welfare: a theoretical treatment of technological change. Cambridge, MA: MIT press.
Paper not yet in RePEc: Add citation now
- Ouellette, L. L. (2012). Do patents disclose useful information. Harvard Journal of Law & Technology 25, 545.
Paper not yet in RePEc: Add citation now
- Pammolli, F., L. Magazzini, and M. Riccaboni (2011). The productivity crisis in pharmaceutical R&D. Nature reviews Drug discovery 10(6), 428–438.
Paper not yet in RePEc: Add citation now
Qian, Y. (2007). Do national patent laws stimulate domestic innovation in a global patenting environment? A cross-country analysis of pharmaceutical patent protection, 1978–2002. The Review of Economics and Statistics 89(3), 436–453.
Sampat, B. and H. L. Williams (2019). How do patents affect follow-on innovation? Evidence from the human genome. American Economic Review 109(1), 203–36.
- Sampat, B. N. and K. C. Shadlen (2021). The COVID-19 innovation system: Article describes innovations that emerged during the COVID-19 pandemic. Health Affairs 40(3), 400–409.
Paper not yet in RePEc: Add citation now
Scherer, F. M. (2010). Pharmaceutical innovation. In B. H. Hall and N. Rosenberg (Eds.), Handbook of the Economics of Innovation, Vol. 1, pp. 539–574. Amsterdam: North-Holland.
Silverberg, G. and B. Verspagen (2005). A percolation model of innovation in complex technology spaces. Journal of Economic Dynamics and Control 29(1-2), 225–244.
Silverberg, G., G. Dosi, and L. Orsenigo (1988). Innovation, diversity and diffusion: a selforganisation model. The Economic Journal 98(393), 1032–1054.
- Sneader, W. (2005). Drug discovery: a history. Chichester, West Sussex: John Wiley & Sons.
Paper not yet in RePEc: Add citation now
- Stiglitz, J. E. (2007). Economic foundations of intellectual property rights. Duke Law Journal 57, 1693.
Paper not yet in RePEc: Add citation now
Stiglitz, J. E. (2016). New theoretical perspectives on the distribution of income and wealth among individuals. In Inequality and Growth: Patterns and Policy, pp. 1–71. London: Palgrave Macmillan.
- Vallée, T. and M. Yıldızoglu (2007). Social and technological efficiency of patent systems. In Innovation, Industrial Dynamics and Structural Transformation, pp. 407–424. Springer.
Paper not yet in RePEc: Add citation now
- Walker, N. (2017). Drug approval trends: Significant acceleration in recent years. Technical report, Pharma’s Almanac. Retrievable at: https://www.pharmasalmanac.com/articles/drugapproval -trends-significant-acceleration-in-recent-years.
Paper not yet in RePEc: Add citation now
Williams, H. L. (2013). Intellectual property rights and innovation: Evidence from the human genome. Journal of Political Economy 121(1), 1–27.
Windrum, P., G. Fagiolo, and A. Moneta (2007). Empirical validation of agent-based models: Alternatives and prospects. Journal of Artificial Societies and Social Simulation 10(2), 8.
- Winter, S. G. (1993). Patents and welfare in an evolutionary model. Industrial and Corporate Change 2(2), 211–231.
Paper not yet in RePEc: Add citation now
Winter, S. G., Y. M. Kaniovski, and G. Dosi (2000). Modeling industrial dynamics with innovative entrants. Structural Change and Economic Dynamics 11(3), 255–293.
Winter, S. G., Y. M. Kaniovski, and G. Dosi (2003). A baseline model of industry evolution. Journal of Evolutionary Economics 13(4), 355–383.